Ruoqian Cheng
Overview
Explore the profile of Ruoqian Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xi L, Cheng R, Zhang M, Pei Z, Ye J, Zhao Z
Transl Pediatr
. 2024 Dec;
13(11):1959-1971.
PMID: 39649642
Background: Mendelian randomization (MR) has been used to identify drug targets in many conditions. Height is a classic complex trait affected by genetic and early-life environmental factors. No systematic screening...
2.
Xi L, Cheng R, He Y, Li X, Ni J, Wu J, et al.
Endocrine
. 2024 Aug;
86(3):1121-1130.
PMID: 39210232
Purpose: The study aimed to evaluate the factors influencing recombinant human growth hormone (rhGH) treatment in Chinese children with short stature born small for gestational age (SGA). Methods: A single-centre,...
3.
Guo H, Fu J, Zhou Y, Luo F, Cheng R
BMC Pediatr
. 2024 Jan;
24(1):32.
PMID: 38200464
Background: Recombinant human growth hormone (rhGH) therapy is beneficial for children with Prader-Willi syndrome (PWS) in improving short stature and metabolism, but the effect of early rhGH treatment on respiratory...
4.
Yuan M, Shan Y, Xu F, Yang L, Sun C, Cheng R, et al.
Transl Pediatr
. 2023 Feb;
12(1):86-96.
PMID: 36798937
Background: Shashi-Pena syndrome (SHAPNS) is a developmental disorder caused by mutations in additional sex combs-like Protein 2 (). Since 2016, only 12 cases from 10 families have been reported. However,...
5.
Cheng R, Zhao Q, Zhong G, Xu J, Zheng Z, Xi L, et al.
Eur J Pharm Sci
. 2022 Oct;
179:106304.
PMID: 36209987
Background And Objectives: PEG-rhGH (Jintrolong®, 0.2 mg/kg/week) is approved in China for the treatment of growth hormone deficiency (GHD) in children. Although 0.2 mg/kg/2 weeks PEG-rhGH failed the non-inferiority threshold...
6.
Luo X, Zhao S, Yang Y, Dong G, Chen L, Li P, et al.
Eur J Endocrinol
. 2022 Sep;
187(5):709-718.
PMID: 36130048
Objective: To evaluate the safety and efficacy of weekly PEGylated-recombinant human growth hormone (PEG-rhGH) in children with idiopathic short stature (ISS) in China. Design And Methods: This was a multicenter,...
7.
Cheng R, Jongman A, Sereno J
Lang Speech
. 2022 Aug;
66(3):533-563.
PMID: 36000389
The current study investigated the merger-in-progress between word-initial nasal and lateral consonants in Fuzhou Min, examining the linguistic and social factors that modulate the merger. First, the acoustic cues to...
8.
Yang L, Liu B, Dong X, Wu J, Sun C, Xi L, et al.
Osteoporos Int
. 2022 Jan;
33(6):1373-1384.
PMID: 35044492
Introduction: Ninety percent of OI cases are caused by pathogenic variants in the COL1A1/COL1A2 gene. The Sillence classification describes four OI types with variable clinical features ranging from mild symptoms...
9.
Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, et al.
Front Endocrinol (Lausanne)
. 2022 Jan;
12:830469.
PMID: 35027911
[This corrects the article DOI: 10.3389/fendo.2021.779365.].
10.
Luo X, Hou L, Zhong Y, You C, Yang Y, Wu X, et al.
Medicine (Baltimore)
. 2021 Dec;
100(51):e28158.
PMID: 34941067
Background: Leuprorelin is an analog of gonadotropin-releasing hormone that is used for the therapy of central precocious puberty (CPP). The aims of this prospective, open label, multicenter clinical trial were...